Lexicon Pharmaceuticals Signs Exclusive Global Licensing Agreement for LX9851 with Novo Nordisk
I'm PortAI, I can summarize articles.
Lexicon Pharmaceuticals Inc. has signed an exclusive global licensing agreement with Novo Nordisk for LX9851, a non-incretin, oral ACSL5 inhibitor for obesity and chronic weight management. The agreement was announced in March 2025. This news was generated by Public Technologies using AI and is based on original content from Lexicon Pharmaceuticals via GlobeNewswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments